Calico(CRC)
Focus: Calico is a publicly-traded biotechnology company focused on aging treatments and related therapeutic areas including oncology, cardiovascular disease, and infectious diseases. The company generated $2.8B in revenue in FY2025 with $564M net income, operating as a well-capitalized biotech player.
Profile data last refreshed 47m ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
15-3 this month
Stable — net -3 jobs in 30d
1 added, 4 removed. Backfill posture.
Should You Work at Calico?
AI assessmentCalico offers financial stability and exposure to aging biology research, but career growth depends on whether early-stage bets translate to clinical validation.
Why Work Here
- Strong financial performance with $2.8B revenue and $564M net income in FY2025 provides stability and investment in R&D
- Growing pipeline with 22 active programs, including promising early-stage oncology and neurology candidates like Fosigotifator (awarded FDA Breakthrough Therapy Designation for Vanishing White Matter Disease in 2026)
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$2.8B
Pipeline & Clinical Trials
DRUG: ABBV-CLS-484
Advanced Solid Tumor CancerClinical Trials (1)
NCT06188975Expanded Access to ABBV-CLS-484
N/AHelp build intelligence for Calico
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.